- Home
- ANTX vs KZIA Comparison
ANTX vs KZIA Comparison
Compare ANTX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | KZIA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 186.7M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ANTX | KZIA |
|---|---|---|
| Price | $3.56 | $7.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.00 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 295.2K | 229.9K |
| Earning Date | 11-11-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $4.86 |
| 52 Week High | $7.19 | $17.40 |
Technical Indicators
Market Signals| Indicator | ANTX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 29.98 | 37.13 |
| Support Level | $2.87 | $6.72 |
| Resistance Level | $5.15 | $8.18 |
| Average True Range (ATR) | 0.33 | 0.68 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 14.64 | 40.26 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.